ASTRAZENECA PLC AZN

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived NYSE

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $58.74B$54.07B$45.81B$44.35B$37.42B$26.62B$24.38B$22.09B$22.46B$23.00B
Operating income $13.74B$10.00B$8.19B$3.76B$1.06B$5.16B$2.92B$3.39B$3.68B$4.90B
Net income $10.23B$7.04B$5.96B$3.29B$115.0M$3.14B$1.23B$2.05B$2.87B$3.41B

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets $114.07B$104.03B$101.12B$96.48B$105.36B$66.73B$61.38B$60.65B$63.35B$62.53B
Total equity $48.72B$40.87B$39.17B$37.06B$39.29B$15.64B$14.60B$14.04B$16.64B$16.67B

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-019130.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 20B 40B 60B Revenue, FY2016: 23B Net income, FY2016: 3.4B Revenue, FY2017: 22.5B Net income, FY2017: 2.9B Revenue, FY2018: 22.1B Net income, FY2018: 2B Revenue, FY2019: 24.4B Net income, FY2019: 1.2B Revenue, FY2020: 26.6B Net income, FY2020: 3.1B Revenue, FY2021: 37.4B Net income, FY2021: 115M Revenue, FY2022: 44.4B Net income, FY2022: 3.3B Revenue, FY2023: 45.8B Net income, FY2023: 6B Revenue, FY2024: 54.1B Net income, FY2024: 7B Revenue, FY2025: 58.7B Net income, FY2025: 10.2B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $23.00B $22.46B $22.09B $24.38B $26.62B $37.42B $44.35B $45.81B $54.07B $58.74B
Gross profit — — — — — — — — — —
Net income $3.41B $2.87B $2.05B $1.23B $3.14B $115.0M $3.29B $5.96B $7.04B $10.23B

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%